Cargando…
Saliva metabolomic profile of COVID-19 patients associates with disease severity
INTRODUCTION: Coronavirus disease 2019 (COVID-19) is strongly linked to dysregulation of various molecular, cellular, and physiological processes that change abundance of different biomolecules including metabolites that may be ultimately used as biomarkers for disease progression and severity. It i...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589589/ https://www.ncbi.nlm.nih.gov/pubmed/36271948 http://dx.doi.org/10.1007/s11306-022-01936-1 |
_version_ | 1784814337297219584 |
---|---|
author | Saheb Sharif-Askari, Narjes Soares, Nelson Cruz Mohamed, Hajer A. Saheb Sharif-Askari, Fatemeh Alsayed, Hawra Ali Hussain Al-Hroub, Hamza Salameh, Laila Osman, Rufaida Satti Mahboub, Bassam Hamid, Qutayba Semreen, Mohammad H. Halwani, Rabih |
author_facet | Saheb Sharif-Askari, Narjes Soares, Nelson Cruz Mohamed, Hajer A. Saheb Sharif-Askari, Fatemeh Alsayed, Hawra Ali Hussain Al-Hroub, Hamza Salameh, Laila Osman, Rufaida Satti Mahboub, Bassam Hamid, Qutayba Semreen, Mohammad H. Halwani, Rabih |
author_sort | Saheb Sharif-Askari, Narjes |
collection | PubMed |
description | INTRODUCTION: Coronavirus disease 2019 (COVID-19) is strongly linked to dysregulation of various molecular, cellular, and physiological processes that change abundance of different biomolecules including metabolites that may be ultimately used as biomarkers for disease progression and severity. It is important at early stage to readily distinguish those patients that are likely to progress to moderate and severe stages. OBJECTIVES: This study aimed to investigate the utility of saliva and plasma metabolomic profiles as a potential parameter for risk stratifying COVID-19 patients. METHOD: LC–MS/MS-based untargeted metabolomics were used to profile the changes in saliva and plasma metabolomic profiles of COVID-19 patients with different severities. RESULTS: Saliva and plasma metabolites were screened in 62 COVID-19 patients and 18 non-infected controls. The COVID-19 group included 16 severe, 15 moderate, 16 mild, and 15 asymptomatic cases. Thirty-six differential metabolites were detected in COVID-19 versus control comparisons. SARS-CoV-2 induced metabolic derangement differed with infection severity. The metabolic changes were identified in saliva and plasma, however, saliva showed higher intensity of metabolic changes. Levels of saliva metabolites such as sphingosine and kynurenine were significantly different between COVID-19 infected and non-infected individuals; while linoleic acid and Alpha-ketoisovaleric acid were specifically increased in severe compared to non-severe patients. As expected, the two prognostic biomarkers of C-reactive protein and D-dimer were negatively correlated with sphingosine and 5-Aminolevulinic acid, and positively correlated with l-Tryptophan and l-Kynurenine. CONCLUSION: Saliva disease-specific and severity-specific metabolite could be employed as potential COVID-19 diagnostic and prognostic biomarkers. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11306-022-01936-1. |
format | Online Article Text |
id | pubmed-9589589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-95895892022-10-24 Saliva metabolomic profile of COVID-19 patients associates with disease severity Saheb Sharif-Askari, Narjes Soares, Nelson Cruz Mohamed, Hajer A. Saheb Sharif-Askari, Fatemeh Alsayed, Hawra Ali Hussain Al-Hroub, Hamza Salameh, Laila Osman, Rufaida Satti Mahboub, Bassam Hamid, Qutayba Semreen, Mohammad H. Halwani, Rabih Metabolomics Original Article INTRODUCTION: Coronavirus disease 2019 (COVID-19) is strongly linked to dysregulation of various molecular, cellular, and physiological processes that change abundance of different biomolecules including metabolites that may be ultimately used as biomarkers for disease progression and severity. It is important at early stage to readily distinguish those patients that are likely to progress to moderate and severe stages. OBJECTIVES: This study aimed to investigate the utility of saliva and plasma metabolomic profiles as a potential parameter for risk stratifying COVID-19 patients. METHOD: LC–MS/MS-based untargeted metabolomics were used to profile the changes in saliva and plasma metabolomic profiles of COVID-19 patients with different severities. RESULTS: Saliva and plasma metabolites were screened in 62 COVID-19 patients and 18 non-infected controls. The COVID-19 group included 16 severe, 15 moderate, 16 mild, and 15 asymptomatic cases. Thirty-six differential metabolites were detected in COVID-19 versus control comparisons. SARS-CoV-2 induced metabolic derangement differed with infection severity. The metabolic changes were identified in saliva and plasma, however, saliva showed higher intensity of metabolic changes. Levels of saliva metabolites such as sphingosine and kynurenine were significantly different between COVID-19 infected and non-infected individuals; while linoleic acid and Alpha-ketoisovaleric acid were specifically increased in severe compared to non-severe patients. As expected, the two prognostic biomarkers of C-reactive protein and D-dimer were negatively correlated with sphingosine and 5-Aminolevulinic acid, and positively correlated with l-Tryptophan and l-Kynurenine. CONCLUSION: Saliva disease-specific and severity-specific metabolite could be employed as potential COVID-19 diagnostic and prognostic biomarkers. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11306-022-01936-1. Springer US 2022-10-22 2022 /pmc/articles/PMC9589589/ /pubmed/36271948 http://dx.doi.org/10.1007/s11306-022-01936-1 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Saheb Sharif-Askari, Narjes Soares, Nelson Cruz Mohamed, Hajer A. Saheb Sharif-Askari, Fatemeh Alsayed, Hawra Ali Hussain Al-Hroub, Hamza Salameh, Laila Osman, Rufaida Satti Mahboub, Bassam Hamid, Qutayba Semreen, Mohammad H. Halwani, Rabih Saliva metabolomic profile of COVID-19 patients associates with disease severity |
title | Saliva metabolomic profile of COVID-19 patients associates with disease severity |
title_full | Saliva metabolomic profile of COVID-19 patients associates with disease severity |
title_fullStr | Saliva metabolomic profile of COVID-19 patients associates with disease severity |
title_full_unstemmed | Saliva metabolomic profile of COVID-19 patients associates with disease severity |
title_short | Saliva metabolomic profile of COVID-19 patients associates with disease severity |
title_sort | saliva metabolomic profile of covid-19 patients associates with disease severity |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589589/ https://www.ncbi.nlm.nih.gov/pubmed/36271948 http://dx.doi.org/10.1007/s11306-022-01936-1 |
work_keys_str_mv | AT sahebsharifaskarinarjes salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity AT soaresnelsoncruz salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity AT mohamedhajera salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity AT sahebsharifaskarifatemeh salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity AT alsayedhawraalihussain salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity AT alhroubhamza salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity AT salamehlaila salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity AT osmanrufaidasatti salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity AT mahboubbassam salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity AT hamidqutayba salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity AT semreenmohammadh salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity AT halwanirabih salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity |